Arena Pharma (ARNA) Tops Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
Go back to Arena Pharma (ARNA) Tops Q1 EPS by 4c
May 12, 2015 8:52 AM EDT
BMO Capital analyst Jim Birchenough reiterated a Market Perform rating and $9 price target on Arena Pharma (NASDAQ: ARNA) following Q1 results, with BELVIQ trends remaining underwhelming.
Birchenough commented, "We are maintaining our Market Perform rating on the shares of ARNA following review of... More
May 11, 2015 4:04 PM EDT
Arena Pharma (NASDAQ: ARNA) announced that its subsidiary, Arena Pharmaceuticals GmbH, and Roivant Sciences Ltd., have entered into a Development, Marketing and Supply Agreement for nelotanserin, Arena's internally discovered inverse agonist of the 5-HT2A receptor. The agreement grants Roivant exclusive worldwide rights to develop and commercialize nelotanserin.
Nelotanserin has been studied to date in multiple clinical trials involving over 900 subjects. Roivant intends to initiate additional Phase 2 clinical trials for the treatment of behavioral and... More
